22157.jpg
Global Medical Foods Markets, 2019-2029 with 2020 as the Base Year
June 22, 2021 06:18 ET | Research and Markets
Dublin, June 22, 2021 (GLOBE NEWSWIRE) -- The "Medical Foods Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021...
Infant Bacterial Therapeutics CFO leaves the company
May 20, 2021 10:30 ET | Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics ABs CFO Daniel Mackey has decided to leave the company to pursue new challenges. He will remain in his current role during his notice period. Michael Owens will be acting...
Infant Bacterial Therapeutics CFO lämnar bolaget
May 20, 2021 10:30 ET | Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics ABs Chief Financial Officer (CFO) Daniel Mackey har bestämt sig för att lämna IBT för att anta nya utmaningar. Han kommer att fortsätta i sin nuvarande roll under...
Annual General Meeting of Infant Bacterial Therapeutics CEO speech
May 06, 2021 12:50 ET | Infant Bacterial Therapeutics AB
CEO Staffan Strömberg's speech at the Annual General Meeting of IBT is available here. The speech is in Swedish. About Infant Bacterial Therapeutics ABInfant Bacterial Therapeutics AB (publ) is a...
VDs anförande i samband med Infant Bacterial Therapeutics årsstämma
May 06, 2021 12:50 ET | Infant Bacterial Therapeutics AB
Verkställande direktören Staffan Strömbergs anförande i samband med IBTs årsstämma 2021 kan ses här   Om Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ) (“IBT”) är ett...
Annual General Meeting of Infant Bacterial Therapeutics
May 04, 2021 11:00 ET | Infant Bacterial Therapeutics AB
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2021, among other things, the following was resolved: adoption of the annual reportthat no dividend is...
Årsstämma i Infant Bacterial Therapeutics
May 04, 2021 11:00 ET | Infant Bacterial Therapeutics AB
På årsstämman i Infant Bacterial Therapeutics AB (publ) den 4 maj 2021 beslutades bland annat följande: fastställande av resultaträkningen och balansräkningen,att ingen utdelning lämnas,beviljad...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2021
May 04, 2021 02:00 ET | Infant Bacterial Therapeutics AB
Message from the CEO IBT is conducting a phase III-study (“The Connection Study”) which is the last phase of the clinical development program with the pharmaceutical candidate IBP-9414 containing...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 mars 2021
May 04, 2021 02:00 ET | Infant Bacterial Therapeutics AB
VD kommenterar Som bekant genomför vi en fas III-studie (“The Connection Study”) vilket är den sista fasen av vårt kliniska utvecklingsprogram med läkemedelskandidaten IBP-9414 som innehåller...
Infant Bacterial Therapeutics expands The Connection Study to include infants with a birth weight below 750 grams
April 29, 2021 16:00 ET | Infant Bacterial Therapeutics AB
After the Data Monitoring Committees’ review Infant Bacterial Therapeutics expands the enrollment criteria of The Connection Study to include 500 - 1000 gram birth weight premature infants.   The...